It doesn’t take much to lure some investors into buying shares in would be biotechnology companies. A cure for cancer, vaccines against common diseases, stem cell therapy and all kinds of weird and wonderful new treatments are grinding their way through the purgatory of Australian biotechs.
Investors love the ‘stories’, and biotech companies like Prima BioMed Limited (ASX: PRR), Prana Biotechnology Limited (ASX: PBT) and Cynata Therapeutics Ltd (ASX: CYP) have experienced massive rises – up to 700%! – in the past. Indeed, one week after I bought Admedus Ltd (ASX: AHZ), I was up 80%.
However, many of these research projects end in failure, either because their treatment/product isn’t successful, or is successful but not significantly better than existing therapies. Even companies that successfully develop a product, like Admedus, can have problems turning their research into cash.
Stop right there
It seems reasonable to say that there is at least a partial correlation between expenditure on research & development (R&D), and achieving outcomes from research. Logically we might say that as more money is spent, the likelihood of achieving an outcome increases.
Investors looking to own the next generation of medical treatments need to forget about loss-making researchers of the type mentioned above. CSL Limited (ASX: CSL) spends enough on R&D every six months to keep a dozen (if not more!) would-be biotech businesses going for a year. The figure was US$283 million at the latest half yearly report – even the successful Sirtex Medical Limited (ASX: SRX) spent just $5 million during the same period.
If you want to own the next generation of life-changing/saving treatments, in terms of R&D expenditure and business expertise, CSL would be one of the best choices on the ASX. Certainly I wish I’d put my $500 into it two years ago, rather than Admedus.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
Motley Fool contributor Sean O'Neill owns shares of Admedus Ltd. and Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- Results: Is G8 Education Ltd a buy for its 4% dividend? – August 27, 2018 12:22pm
- Results: Why the Adacel Technologies Limited (ASX:ADA) share price is down 7% – August 26, 2018 9:54pm
- Results: Why the Nearmap Ltd (ASX:NEA) share price is up 4% today – August 22, 2018 5:15pm